ES2190456T3 - Combinacion de inhibidores de la proteasa del vih. - Google Patents

Combinacion de inhibidores de la proteasa del vih.

Info

Publication number
ES2190456T3
ES2190456T3 ES95930118T ES95930118T ES2190456T3 ES 2190456 T3 ES2190456 T3 ES 2190456T3 ES 95930118 T ES95930118 T ES 95930118T ES 95930118 T ES95930118 T ES 95930118T ES 2190456 T3 ES2190456 T3 ES 2190456T3
Authority
ES
Spain
Prior art keywords
combination
hiv
hiv protease
protease inhibitors
proteasa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95930118T
Other languages
English (en)
Inventor
Paul J Deutsch
Emilio A Emini
Joseph P Vacca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2190456T3 publication Critical patent/ES2190456T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA COMBINACION DEL COMPUESTO J INHIBIDOR DE PROTEASA HIV Y UNO O MAS DE OTROS POTENTES INHIBIDORES DE LA PROTEASA HIV ES UTIL EN LA INHIBICION DE LA PROTEASA HIV, LA PREVENCION O TRATAMIENTO DE LA INFECCION POR HIV, EN COMPUESTOS, SALES ACEPTABLES FARMACEUTICAMENTE, INGREDIENTES DE COMPOSICIONES FARMACEUTICAS, EN COMBINACION O NO CON OTROS ANTIVIRALES, INMUNOMODULADORES, ANTIBIOTICOS O VACUNAS. TAMBIEN SE DESCRIBEN METODOS PARA TRATAR EL SIDA Y METODOS PARA PREVENIR O TRATAR LA INFECCION POR HIV.
ES95930118T 1994-08-11 1995-08-07 Combinacion de inhibidores de la proteasa del vih. Expired - Lifetime ES2190456T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28947494A 1994-08-11 1994-08-11
US33936994A 1994-11-14 1994-11-14
US49246195A 1995-07-20 1995-07-20

Publications (1)

Publication Number Publication Date
ES2190456T3 true ES2190456T3 (es) 2003-08-01

Family

ID=27403895

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95930118T Expired - Lifetime ES2190456T3 (es) 1994-08-11 1995-08-07 Combinacion de inhibidores de la proteasa del vih.

Country Status (19)

Country Link
EP (1) EP0774969B8 (es)
JP (1) JPH10504036A (es)
KR (1) KR970704441A (es)
CN (1) CN1101190C (es)
AT (1) ATE232727T1 (es)
AU (1) AU698664B2 (es)
CA (1) CA2197207C (es)
CY (1) CY2360B1 (es)
CZ (1) CZ292577B6 (es)
DE (1) DE69529678T2 (es)
DK (1) DK0774969T3 (es)
ES (1) ES2190456T3 (es)
HU (1) HUT76540A (es)
IL (1) IL114808A (es)
MX (1) MX9701121A (es)
NO (1) NO314168B1 (es)
PL (1) PL181578B1 (es)
SK (1) SK18197A3 (es)
WO (1) WO1996004913A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
CA2270546A1 (en) * 1996-11-08 1998-05-22 Japan Energy Corporation Aids remedy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US517041A (en) * 1894-03-27 Fruit-picker
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
CA2096408C (en) * 1990-11-19 2005-02-08 Gary Anthony Decrescenzo Retroviral protease inhibitors
DK0558657T3 (da) * 1990-11-19 1997-07-07 Monsanto Co Retrovirale proteaseinhibitorer
IE913840A1 (en) * 1990-11-20 1992-05-20 Abbott Lab Retroviral protease inhibiting compounds
ATE163926T1 (de) * 1991-11-08 1998-03-15 Merck & Co Inc Hiv-protease-inhibitoren verwendbar in der aids- behandlung
EP1302468B1 (en) * 1992-12-29 2008-12-17 Abbott Laboratories Processes and intermediates for manufacturing retroviral protease inhibiting compounds

Also Published As

Publication number Publication date
NO970632L (no) 1997-04-10
CA2197207A1 (en) 1996-02-22
SK18197A3 (en) 1997-09-10
ATE232727T1 (de) 2003-03-15
CA2197207C (en) 2006-10-17
NO970632D0 (no) 1997-02-11
DE69529678T2 (de) 2003-09-25
HUT76540A (en) 1997-09-29
EP0774969B1 (en) 2003-02-19
PL318506A1 (en) 1997-06-23
AU698664B2 (en) 1998-11-05
AU3361195A (en) 1996-03-07
IL114808A (en) 1999-10-28
CN1101190C (zh) 2003-02-12
CZ292577B6 (cs) 2003-10-15
JPH10504036A (ja) 1998-04-14
EP0774969B8 (en) 2003-07-02
MX9701121A (es) 1997-05-31
EP0774969A1 (en) 1997-05-28
DE69529678D1 (de) 2003-03-27
KR970704441A (ko) 1997-09-06
IL114808A0 (en) 1995-12-08
NO314168B1 (no) 2003-02-10
PL181578B1 (pl) 2001-08-31
CN1160350A (zh) 1997-09-24
WO1996004913A1 (en) 1996-02-22
CY2360B1 (en) 2004-06-04
CZ38997A3 (en) 1997-11-12
DK0774969T3 (da) 2003-03-31

Similar Documents

Publication Publication Date Title
ES2125251T3 (es) Inhibidores de la proteasa del vih.
ATE377011T1 (de) Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1- piperazinpentanamide als hiv-proteasehemmer
ES2151897T3 (es) Benzoxazinonas como inhibidores de la transcriptasa inversa de vih.
ES2177868T3 (es) Hidroxietilaminosulfonamidas de alfa- y beta-aminoacidos utiles como inhibidores de proteasas retroviricas.
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
MY142948A (en) Benzophenones as inhibitors of reverse transcriptase
MX9204720A (es) Derivados de quinazolina como inhibidores de transcriptasa inversa de vih.
ES2178036T3 (es) Derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que le contienen.
ES2150933T3 (es) Inhibidores de la proteasa vih utiles para el tratamiento del sida.
DE69531944D1 (de) Neue hiv-protease-inhibitoren
ES2174921T3 (es) Inhibidores de la proteasa del vih.
ES2101252T3 (es) Inhibidores de la proteasa del hiv utiles para el tratamiento del sida.
MX9705916A (es) Terapia de combinacion para infeccion por vih usando el inhibidor de proteasa de vih indinavir y el inhibidor de transcriptasa inversa 3tc, opcionalmente junto con azt, ddi, o ddc.
ES2096874T3 (es) Inhibidor de la proteasa de hiv util para el tratamiento del sida.
ES2190456T3 (es) Combinacion de inhibidores de la proteasa del vih.
MX9700036A (es) Combinacion de compuestos, uso en la preparacion de composiciones para tratar infeccion por el vir s de inmunodeficiencia humana, y composiciones obtenidas.
AR013758A1 (es) Terapia de combinacion para el tratamiento de sida.
ATE238062T1 (de) Hemmung von hiv-infektion
DOP2002000449A (es) Sal sodica de un inhibidor de integradasa del vih.
ECSP982741A (es) Terapia combinada para el tratamiento del sida
FI970565A0 (fi) HIV-proteaasia inhiboiva yhdistelmä
ECSP961660A (es) Terapia combinada para infeccion por vih
MX9304351A (es) Inhibidores de proteasas de aminodiol y composiciones farmaceuticas que los incluyen.